StockData

Ascentage Pharma Group International vs Innoviva

AAPG and INVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AAPG and INVA compare

Innoviva grew revenue faster over the last twelve months (12.8% versus −41.5% for Ascentage Pharma Group International).

Innoviva scores higher on the StockData Score (14 against 3 for Ascentage Pharma Group International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAAPGINVA
Size and price
Market cap–$1.3B
Share price$13.14$18.30
Change, 1 year−61.7%−17.8%
Change, 5 years–8.2%
Beta (5Y)1.430.20
Employees767159
StockData Score
Total score314 (better)
Valuation score05 (better)
Growth score12 (better)
Performance score11
Health score16 (better)
Dividend score00
Valuation
P/E–9.3×
P/S–3.0×
P/B–1.2×
EV/EBITDA–5.9×
P/FCF–7.2×
PEG–0.80
FCF yield–13.8%
Fair value–$30.22
Margin of safety–39.5%
Growth
Revenue growth (TTM)−41.5%12.8% (better)
Revenue growth, 5Y average–4.1%
EPS growth, 5Y average–10.3%
Profitability
Gross margin91.5% (better)74.5%
Operating margin–38.8%
Net margin−216%–
FCF margin−209%41.6% (better)
Return on equity−156%–
Return on invested capital–18.0%
Financial health
Debt / equity1.500.23 (better)
Net debt / EBITDA–−1.90
Interest coverage–8.6×
Current ratio1.7915.44 (better)
Altman Z-score–3.47
Dividends and buybacks
Buyback yield–5.9%
Shareholder yield–5.9%
Ownership
Held by institutions0.00%104%
Held by insiders13.0%5.4%
Short interest, % of float–11.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.